The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.
about
Current perspectives on HIV-1 antiretroviral drug resistanceComparison of predicted susceptibility between genotype and virtual phenotype HIV drug resistance interpretation systems among treatment-naive HIV-infected patients in Asia: TASER-M cohort analysis.Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants.Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.Bayesian network analyses of resistance pathways against efavirenz and nevirapine.Improving HIV proteome annotation: new features of BioAfrica HIV Proteomics Resource.HIV-1 drug resistance mutations: an updated framework for the second decade of HAARTAnalysis of nevirapine resistance mutations in cloned HIV type 1 variants from HIV-infected Ugandan infants using a single-step amplification-sequencing method (AmpliSeq).Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations.Use of tissue culture cell lines to evaluate HIV antiviral resistance.Mining protein dynamics from sets of crystal structures using "consensus structures".Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.The frequency of HIV-I drug resistance mutations among treatment-naive individuals at a tertiary care centre in south India.HIV Reverse Transcriptase and Protease Genes Variability Can Be a Biomarker Associated with HIV and Hepatitis B or C Coinfection.
P2860
Q26852626-67277B80-B46E-4ADF-BF05-1F5864C0C297Q34457230-951B7A0B-068E-473F-B2BC-BE95733BDE93Q35140450-3FB0300E-E2C0-497F-8A80-3EA6E1035722Q36146704-3B1BE9F2-8B3C-466A-B79D-9B9A8B398F7DQ36677558-3954EA1E-845B-4E5B-BC39-65075CD652A5Q36805433-F901010D-A50A-461F-8F6E-95FC6925999AQ36900010-7FF89930-162C-4B77-85F3-789E3A496ADEQ36926027-DDA7BE41-8A2D-4040-98B9-4D66471974ACQ37409842-15D3C713-7D30-41D1-8321-55916606C075Q39955277-4E6DA4AD-C472-4E04-8EB7-962FB9C6FAC7Q40454703-486C1428-B4F1-4711-AE40-D9A918656784Q42101552-7A036093-602A-4666-9534-B9BFAD38E808Q48069028-ECBDC353-738D-4C1E-A98C-7B230B84B98DQ55020251-EB907909-A816-438A-8B5F-0D981A41724B
P2860
The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The K101P and K103R/V179D muta ...... erse transcriptase inhibitors.
@en
type
label
The K101P and K103R/V179D muta ...... erse transcriptase inhibitors.
@en
prefLabel
The K101P and K103R/V179D muta ...... erse transcriptase inhibitors.
@en
P2093
P2860
P1476
The K101P and K103R/V179D muta ...... erse transcriptase inhibitors.
@en
P2093
Colombe Chappey
Neil T Parkin
Soumi Gupta
P2860
P304
P356
10.1128/AAC.50.1.351-354.2006
P407
P577
2006-01-01T00:00:00Z